Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

Gene therapy research is expensive. Biotechs invest millions of dollars in early research to develop therapies for conditions that might be rare. But when funds are limited and the market potential is dim, such programs are often abandoned by companies, leaving patients and investigators in a bind.

In this month’s cover story, we take a look at one such case where a hospital network is trying to save access to a gene therapy program for a rare disorder called adenosine deaminase deficient-severe combined immunodeficiency (ADA-SCID).

Also in this issue, we explore how generative artificial intelligence (genAI) is influencing drug discovery and the market’s reaction to drugs developed using AI. We also explore the challenges with clinical trials gathering more data than ever before and the burden this may place on patients and investigators. All this, along with the latest news and deals in the pharmaceutical landscape. 

Manasi Vaidya, editor